Skip to main content

You are here

Georgia

Tuberculosis (TB) represents a significant public health issue in Georgia, where MSF activities focus on patients with the multidrug-resistant form of the disease.

Médecins Sans Frontières first worked in Georgia in 1993, and teams were present in the aftermath of the Russo-Georgian War in 2008.

Armed Conflict Response 

Georgia has experienced a number of conflicts. Internal tensions between Georgian and South Ossetian peoples have, on multiple occasions, transformed into outright ethnic conflict. MSF emergency teams have been present in Tsbilisi, as well as the separatist province of South Ossetia during times of conflict. MSF  distributed basic relief supplies, and provided psychological support and medical assistance to displaced people. 

Treating multidrug-resistant Tuberculosis 

MSF has been focusing its activities in Georgia around the introduction of new treatments for multidrug-resistant Tuberculosis (MDR-TB) patients. 

Approximately 10 per cent of MDR-TB patients have extensively drug-resistant TB (XDR-TB). Current treatment outcomes for these patients are poor, notably because of the length, complexity and toxicity of existing regimens.

Georgia hosts one of the sites for the endTB clinical trial, which aims to compare the safety and efficacy of different MDR-TB regimens containing bedaquiline and/or delamanid. The trial involves a shorter regimen (nine months instead of two years) based on the two new drugs, which are taken orally.

The project is a partnership between MSF and Partners in Health and Innovative Research and Development, which aims to find shorter, less toxic and more effective treatments for drug-resistant TB (DR-TB), through access to new drugs, clinical trials and advocacy at country and global level.